Celularity Receives Nasdaq Notice for Late 10-K Filing
Event summary
- Celularity Inc. received a Nasdaq notice on April 16, 2026, for failing to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
- The company has 60 calendar days to submit a compliance plan to Nasdaq.
- Nasdaq may grant an exception of up to 180 calendar days if the plan is accepted.
- Celularity expects to file the Form 10-K in the coming weeks but cannot guarantee compliance within any granted period.
The big picture
Celularity's delay in filing its Annual Report on Form 10-K highlights the regulatory scrutiny faced by biotech companies, particularly those in the regenerative medicine space. The company's ability to submit a compliance plan and regain compliance will be critical in maintaining its listing status and investor trust. This event underscores the importance of timely financial reporting in the biotech sector, where regulatory compliance and transparency are paramount.
What we're watching
- Compliance Risk
- Whether Celularity can regain compliance with Nasdaq Listing Rule 5250(c)(1) within the granted exception period.
- Execution Risk
- The pace at which Celularity completes its year-end financial reporting and audit processes.
- Market Confidence
- How the delay in filing the Form 10-K affects investor confidence and stock performance.
Related topics